James Q. Del Rosso, DO, FAOCD; Valley Hospital Medical Center, Las Vegas, Nevada

Howard Sofen, MD; Dermatology Associates, Los Angeles, California;

Barry Leshin, MD; The Skin Surgery Center, Winston-Salem, North Carolina

TC Meng, MD; James Kulp, BS and Sharon Levy, MD, Graceway Pharmaceuticals, Bristol, Tennessee Read the rest of this article »

Ellen Frankel, MD,St. Joseph’s Hospital, Providence, Rhode Island

Mark W. Trumbore, PhD, Collegium Pharmaceutical, Cumberland, Rhode Island

Disclosure: Dr. Frankel has received research support from Onset Therapeutics. Dr. Trumbore is employed by Collegium Pharmaceutical. Read the rest of this article »

Michael H. Gold, MD, Tennessee Clinical Research Center, Nashville, Tennessee;

Anneke Andriessen; RBC Consultants, The Netherlands

Julie Biron, Tennessee Clinical Research Center, Nashville, Tennessee;

Disclosure: Dr. Gold is a consultant to, performs research for, speaks for, and receives honoraria from Pharos Life; Ms. Andriessen and Ms. Biron report no relevant conflicts of interest. Read the rest of this article »

William Kirby, DO, FAOCD; Dr. Tattoff Inc., Beverly Hills, California;

Alpesh Desai, DO, FAOCD and Tejas Desai, DO, FAOCD; Heights Dermatology, Houston, Texas;

Francisca Kartono, DO; Department of Dermatology, Botsford Hospital, Farmington Hills, Michigan

Geeta Patel, BS, New York College of Osteopathic Medicine, Old Westbury, New York Read the rest of this article »

Michael H. Gold, MD; Tennessee Clinical Research Center, Nashville, Tennessee; Anneke Andriessen; RBC Consultants, The Netherlands; Julie Biron; Tennessee Clinical Research Center, Nashville, Tennessee; Hinke Andriessen; RBC Consultants, The Netherlands Read the rest of this article »

Leon H. Kircik, MD
DermResearch PLLC, Louisville, Kentucky; Indiana University, School of Medicine, Louisville, Kentucky Read the rest of this article »

Robin Ashinoff, MD, Director, Dermatologic, Mohs and Laser Surgery, Hackensack and University Medical Center, Hackensack, New Jersey; Vicki J. Levine, MD, Chief, Dermatologic and Mohs Surgery, New York University Medical Center, New York, New York; Alexa B. Steuer,  Cresskill High School, Cresskill, New Jersey, Carly Sedwick, Quinnipiac College, Hamden, Connecticut Read the rest of this article »

An Investigator-Blind, Randomized, Parallel-Group Study

by [a]Lawrence J. Green, MD, and [b]James Q. Del Rosso, DO, FAOCD

[a]George Washington University, Washington, DC;

[b]Clinical Associate Professor (Dermatology), University of Nevada School of Medicine and Touro University College of Osteopathic Medicine; Dermatology Residency Director, Valley Hospital Medical Center and Las Vegas Skin and Cancer Clinics, Las Vegas and Henderson, Nevada

Disclosure: Dr. Green is an investigator for this study. Dr. Del Rosso is a consultant to, speaker for, and performs research for Obagi Medical Products, Arcutis, Allergan, Coria, Galderma, Graceway, Intendis, Medicis, Onset, OrthoNeutrogena, PharmaDerm, Quinnova, Ranbaxy, SkinMedica, Stiefel, Triax, Unilever, and Warner Chilcott. Read the rest of this article »

by Dow Stough, MD, Burke Pharmaceutical Research, Hot Springs, Arkansas; Alicia D. Bucko, DO, Academic Dermatology Associates, Albuquerque, New Mexico; George Vamvakias, BS, sanofi-aventis, Malvern, Pennsylvania; Elyse S. Rafal, MD;  DermResearchCenter of New York, Inc., Stony Brook, New York; and Steven A. Davis, MD, Dermatology Clinical Research Center of San Antonio™, San Antonio, Texas

Read the rest of this article »

by Amy Forman Taub, MD, Assistant Clinical Professor of Dermatology, Northwestern University Medical School, Chicago, Illinois; Founder/Director of Advanced Dermatology, Skinfo, SkinQRI, Lincolnshire, Illinois

Erin C. DeVita, CST, CMSLO, CCRC, Advanced Dermatology, SkinQRI, Lincolnshire, Illinois

Abstract

Introduction: Many laser and light devices have reported to be successful in the treatment of the flushing, background erythema, and telangiectasias that characterize erythematotelangiectatic rosacea including pulsed dye laser, potassium titanyl phosphate, intense pulsed light, and dual-wavelength lasers. A technology called ELOS (electro-optical synergy) combines pulsed light or laser with bipolar radiofrequency. This combination, developed in 2000, was based on the premise that these two forms of energy could be synergistic. One such device (Aurora SRA—skin-rejuvenation advanced handpiece, Syneron Medical Ltd., Yokneam, Israel) has a light spectrum of 470 to 980nm, energy up to 45J/cm2, and a range of radiofrequency energy of 5 to 25J/cm3 and is indicated for the treatment of vascular and pigmented lesions. Methods: We attempted to quantify the improvement of moderate-to-severe type-1 rosacea after three and five full-face treatments with this modality. Twenty-one patients with moderate-to-severe rosacea underwent five monthly full-face treatments with this device. The patients were evaluated with high-resolution photographs (Canfield Visia CR, Canfield, Fairfield, New Jersey) and self-evaluated via the National Rosacea Society’s official “Scorecard.” Results: Erythema and telangiectasia (physician assessed) as well as flushing and global status (patient assessed) achieved improvement that was statistically significant. Five treatments were no more effective than three, although the photographs reveal subtle improvements. There were no significant adverse events. Conclusion: The results of this study suggest that the combination of optical and RF energies is effective for the treatment of rosacea. ELOS, as well as other vascular-focused lasers and light sources, provides an important treatment option for patients who fail medical therapy, reach a plateau in their response to medical therapy, or wish to avoid chronic oral therapy. Read the rest of this article »